In response to the COVID-19 global pandemic, Lifescient is repurposing an existing FDA approved drug to develop a treatment for COVID-19.

Recognizing that the COVID-19 virus attacks the lungs via the nasal mucosa causing inflammatory lung and upper respiratory damage, Lifescient is developing a generic drug that has demonstrated antiviral activity against SARS-CoV-2 virus, to treat COVID-19.

Lifescient is working on developing a combination of this drug with another generic FDA approved drug clinically proven to enhance pulmonary bioavailability. This combination, when delivered in a targeted manner to the lungs, will result in a synergistic reduction in inflammation and elimination of the virus.

Since the drug is generic and freely available from multiple vendors, potential manufacturing and supply chain challenges are avoided and market demand can be met now and in the future by making available a highly affordable drug for people all over the world.

Lifescient is seeking partners to develop, manufacture, and supply the potential treatment for COVID-19. We will achieve this by entering into alliances and joint ventures with pharmaceutical companies and strategic partners.

SUBSCRIBE